<p>西雅圖，2025 年 12 月 09 日（全球新聞通訊社）——Adaptive Biotechnologies Corporation（納斯達克：ADPT）是一家商業階段的生物技術公司，旨在將適應性免疫系統的遺傳學轉化為臨牀產品，以診斷和治療疾病。今天宣佈，首席科學官兼聯合創始人哈蘭·羅賓斯博士和首席商業官蘇珊·博布爾斯基將參加傑富瑞的爐邊談話，討論血液學/腫瘤學中的最小殘留病（MRD），並深入探討 clonoSEQ 檢測技術。此次電話會議將於 2025 年 12 月 11 日（星期四）東部時間下午 2:00 至 3:00 舉行。有興趣的各方可以聯繫他們的傑富瑞銷售代表以獲取詳細信息。</p>
<p><strong>關於 Adaptive Biotechnologies</strong></p>
<p>Adaptive Biotechnologies（“我們” 或 “我們的”）是一家商業階段的生物技術公司，專注於利用適應性免疫系統的固有生物學來轉變疾病的診斷和治療。我們相信，適應性免疫系統是自然界對大多數疾病最精細的診斷和治療工具，但解碼能力的缺乏使醫學界無法充分利用其潛力。我們的專有免疫醫學平台以規模、精度和速度揭示並轉化適應性免疫系統的龐大遺傳信息。我們將我們的平台應用於與生物製藥公司合作，提供藥物開發信息，並在最小殘留病（MRD）和免疫醫學兩個業務領域開發臨牀診斷。我們的商業產品和臨牀管道使得能夠診斷、監測和治療癌症及自身免疫性疾病等疾病。我們的目標是開發和商業化針對每位患者量身定製的免疫驅動臨牀產品。</p>
<p><strong>適應性投資者</strong></p>
<p>卡里娜·卡爾薩迪拉，投資者關係及財務規劃與分析副總裁</p>
<p>201-396-1687</p>
<p>investors@adaptivebiotech.com</p>
<p><strong>適應性媒體</strong></p>
<p>埃裏卡·瓊斯，企業傳播副總監</p>
<p>206-279-2423</p>
<p>media@adaptivebiotech.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UWTVOQ00zTXpFME5UYzRJekl4TnpjeE9EST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UWTVOQ00zTXpFME5UYzRJekl4TnpjeE9EST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZjcxMGZkYjMtMmYyYS00ZTEyLTk5MmMtNmE2Y2FjMTc4ZDcwLTExODg3NTItMjAyNS0xMi0wOS1lbg==/tiny/Adaptive-Biotechnologies.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZjcxMGZkYjMtMmYyYS00ZTEyLTk5MmMtNmE2Y2FjMTc4ZDcwLTExODg3NTItMjAyNS0xMi0wOS1lbg==/tiny/Adaptive-Biotechnologies.png"/></p>

ADPT

<p>Adaptive Biotechnologies 將於 2025 年 12 月 11 日參加 Jefferies 的爐邊談話，討論血液學/腫瘤學中的微小殘留病（MRD）和 clonoSEQ 檢測技術。Harlan Robins 博士和 Susan Bobulsky 將代表公司出席。Adaptive Biotechnologies 專注於通過適應性免疫系統轉變疾病的診斷和治療。該活動對有興趣的各方開放，參與者可以通過 Jefferies 的銷售代表進行聯繫</p>

<p>SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced Dr. Harlan Robins, Chief Scientific Officer and Co-Founder and Susan Bobulsky, Chief Commercial Officer, MRD will be participating in a Jefferies fireside chat to discuss Minimal Residual Disease (MRD) in Hematology/Oncology with deep dive into the clonoSEQ assay technology. The call will take place on Thursday, December 11, 2025, from 2:00 p.m. to 3:00 p.m. Eastern Time. Interested parties may reach out to their Jefferies sales representative for details.</p>
<div class="lb-trans"><p>西雅圖，2025 年 12 月 09 日（全球新聞通訊社）——Adaptive Biotechnologies Corporation（納斯達克：ADPT）是一家商業階段的生物技術公司，旨在將適應性免疫系統的遺傳學轉化為臨牀產品，以診斷和治療疾病。今天宣佈，首席科學官兼聯合創始人哈蘭·羅賓斯博士和首席商業官蘇珊·博布爾斯基將參加傑富瑞的爐邊談話，討論血液學/腫瘤學中的最小殘留病（MRD），並深入探討 clonoSEQ 檢測技術。此次電話會議將於 2025 年 12 月 11 日（星期四）東部時間下午 2:00 至 3:00 舉行。有興趣的各方可以聯繫他們的傑富瑞銷售代表以獲取詳細信息。</p>
</div><p><strong>About Adaptive Biotechnologies</strong></p>
<div class="lb-trans"><p><strong>關於 Adaptive Biotechnologies</strong></p>
</div><p>Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.</p>
<div class="lb-trans"><p>Adaptive Biotechnologies（“我們” 或 “我們的”）是一家商業階段的生物技術公司，專注於利用適應性免疫系統的固有生物學來轉變疾病的診斷和治療。我們相信，適應性免疫系統是自然界對大多數疾病最精細的診斷和治療工具，但解碼能力的缺乏使醫學界無法充分利用其潛力。我們的專有免疫醫學平台以規模、精度和速度揭示並轉化適應性免疫系統的龐大遺傳信息。我們將我們的平台應用於與生物製藥公司合作，提供藥物開發信息，並在最小殘留病（MRD）和免疫醫學兩個業務領域開發臨牀診斷。我們的商業產品和臨牀管道使得能夠診斷、監測和治療癌症及自身免疫性疾病等疾病。我們的目標是開發和商業化針對每位患者量身定製的免疫驅動臨牀產品。</p>
</div><p><strong>ADAPTIVE INVESTORS</strong></p>
<div class="lb-trans"><p><strong>適應性投資者</strong></p>
</div><p>Karina Calzadilla, Vice President, Investor Relations and FP&amp;A</p>
<div class="lb-trans"><p>卡里娜·卡爾薩迪拉，投資者關係及財務規劃與分析副總裁</p>
</div><p>201-396-1687</p>
<div class="lb-trans"><p>201-396-1687</p>
</div><p>investors@adaptivebiotech.com</p>
<div class="lb-trans"><p>investors@adaptivebiotech.com</p>
</div><p><strong>ADAPTIVE MEDIA</strong></p>
<div class="lb-trans"><p><strong>適應性媒體</strong></p>
</div><p>Erica Jones, Associate Corporate Communications Director</p>
<div class="lb-trans"><p>埃裏卡·瓊斯，企業傳播副總監</p>
</div><p>206-279-2423</p>
<div class="lb-trans"><p>206-279-2423</p>
</div><p>media@adaptivebiotech.com</p>
<div class="lb-trans"><p>media@adaptivebiotech.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UWTVOQ00zTXpFME5UYzRJekl4TnpjeE9EST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5OTY5NCM3MzE0NTc4IzIxNzcxODI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZjcxMGZkYjMtMmYyYS00ZTEyLTk5MmMtNmE2Y2FjMTc4ZDcwLTExODg3NTItMjAyNS0xMi0wOS1lbg==/tiny/Adaptive-Biotechnologies.png" alt="" original-src="https://ml.globenewswire.com/media/ZjcxMGZkYjMtMmYyYS00ZTEyLTk5MmMtNmE2Y2FjMTc4ZDcwLTExODg3NTItMjAyNS0xMi0wOS1lbg==/tiny/Adaptive-Biotechnologies.png"/></p>

Adaptive Biotechnologies 將參與 Jefferies 爐邊談話系列，討論微小殘留病 | ADPT 股票新聞